NeuroDerm

@NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders.

ಜೂನ್ 2016 ಸಮಯದಲ್ಲಿ ಸೇರಿದ್ದಾರೆ

ಟ್ವೀಟ್‌ಗಳು

ನೀವು @NeuroDerm ಅವರನ್ನು ತಡೆಹಿಡಿದಿರುವಿರಿ

ಈ ಟ್ವೀಟ್‌ಗಳನ್ನು ವೀಕ್ಷಿಸಲು ನೀವು ಖಚಿತವಾಗಿ ಬಯಸುವಿರಾ? ಟ್ವೀಟ್ ವೀಕ್ಷಣೆಯು @NeuroDerm ಅವರ ತಡೆತೆರವುಗೊಳಿಸುವುದಿಲ್ಲ

  1. 20 ಗಂಟೆಗಳ ಹಿಂದೆ

    Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash:

  2. ಜೂನ್ 27

    Results of ND0612H Phase II Trial Presented at the 3rd Congress of the European Academy of Neurology

  3. ಜೂನ್ 8

    NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders -

  4. ಜೂನ್ 6

    European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial -

  5. ಜೂನ್ 5

    Presents ND0612H Ph. II Trial Results at the 21st Intl. Congress of Parkinson’s Disease + Movement Disorders

  6. ಮೇ 30

    NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017 -

  7. ಮೇ 23

    ND0612H Ph. 2 Results to be Presented at the 21st International Congress of Parkinson’s Disease + Movement Disorders

  8. ಮೇ 11

    NeuroDerm Announces First Quarter 2017 Financial Results -

  9. ಏಪ್ರಿ 24

    NeuroDerm is proud to participate in this year’s and help to make a difference

  10. ಏಪ್ರಿ 24

    Oded Lieberman, CEO, introducing ND0901, a pre-clinical continuous subcutaneous LD/CD delivery, at our Investor Day.

  11. ಏಪ್ರಿ 20

    NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk -

  12. ಏಪ್ರಿ 10

    NeuroDerm A minute can make a huge difference in the lives of Parkinson’s patients and worldwide awareness!

  13. ಏಪ್ರಿ 10

    NeuroDerm to Host Investor Day on April 21, 2017 -

  14. ಮಾರ್ಚ್ 30

    NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results -

  15. ಮಾರ್ಚ್ 21

    NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017 -

  16. ಮಾರ್ಚ್ 1

    NDRM Achieves Primary Endpoint in ND0612H Ph.2 Trial; Seeks Broader EU Label Based on iNDiGO Trial Post EMA Meeting-

  17. ಫೆಬ್ರ 27

    NeuroDerm CEO to Present at Upcoming Investor Conferences -

  18. ಜನ 26

    NeuroDerm Announces Extraordinary General Meeting Of Shareholders -

  19. ಜನ 3

    NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017 -

  20. ಡಿಸೆಂ 22,2016

    NDRM Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares -

ಲೋಡಿಂಗ್ ಸಮಯ ಸ್ವಲ್ಪ ತೆಗೆದುಕೊಳ್ಳುತ್ತಿರುವಂತೆನಿಸುತ್ತದೆ.

Twitter ಸಾಮರ್ಥ್ಯ ಮೀರಿರಬಹುದು ಅಥವಾ ಕ್ಷಣಿಕವಾದ ತೊಂದರೆಯನ್ನು ಅನುಭವಿಸುತ್ತಿರಬಹುದು. ಮತ್ತೆ ಪ್ರಯತ್ನಿಸಿ ಅಥವಾ ಹೆಚ್ಚಿನ ಮಾಹಿತಿಗೆ Twitter ಸ್ಥಿತಿಗೆ ಭೇಟಿ ನೀಡಿ.

    ಇದನ್ನೂ ಸಹ ನೀವು ಇಷ್ಟಪಡಬಹುದು

    ·